Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein.

Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, Pfaff JM, Xiang X, Doranz BJ, de Silva AM, Austin SK, Sukupolvi-Petty S, Diamond MS, Crowe JE Jr.

MBio. 2013 Nov 19;4(6):e00873-13. doi: 10.1128/mBio.00873-13.

2.

Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection.

Sukupolvi-Petty S, Brien JD, Austin SK, Shrestha B, Swayne S, Kahle K, Doranz BJ, Johnson S, Pierson TC, Fremont DH, Diamond MS.

J Virol. 2013 Aug;87(16):8826-42. doi: 10.1128/JVI.01314-13. Epub 2013 Jun 19.

3.

Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus.

Brien JD, Sukupolvi-Petty S, Williams KL, Lam CY, Schmid MA, Johnson S, Harris E, Diamond MS.

J Virol. 2013 Jul;87(13):7747-53. doi: 10.1128/JVI.00327-13. Epub 2013 May 8.

4.

Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected].

Williams KL, Sukupolvi-Petty S, Beltramello M, Johnson S, Sallusto F, Lanzavecchia A, Diamond MS, Harris E.

PLoS Pathog. 2013 Feb;9(2):e1003157. doi: 10.1371/journal.ppat.1003157. Epub 2013 Feb 14. Erratum in: PLoS Pathog. 2013 Mar;9(3). doi:10.1371/annotation/e08f911a-15ec-46d0-bede-83fdf3af1801.

5.

Mosquito bite delivery of dengue virus enhances immunogenicity and pathogenesis in humanized mice.

Cox J, Mota J, Sukupolvi-Petty S, Diamond MS, Rico-Hesse R.

J Virol. 2012 Jul;86(14):7637-49. doi: 10.1128/JVI.00534-12. Epub 2012 May 9.

6.

In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection.

de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WM, Kraus A, Olivarez NP, Pham Q, Brien JD, Tsai WY, Wang WK, Halstead S, Kliks S, Diamond MS, Baric R, Lanzavecchia A, Sallusto F, de Silva AM.

PLoS Negl Trop Dis. 2011 Jun;5(6):e1188. doi: 10.1371/journal.pntd.0001188. Epub 2011 Jun 21. Erratum in: PLoS Negl Trop Dis. 2011 Aug;5(8). doi: 10.1371/annotation/f585335f-ff77-40ae-a8b6-ad6019af31aa. Brian, James [corrected to Brien, James D].

7.

The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.

Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F.

Cell Host Microbe. 2010 Sep 16;8(3):271-83. doi: 10.1016/j.chom.2010.08.007.

8.

Genotype-specific neutralization and protection by antibodies against dengue virus type 3.

Brien JD, Austin SK, Sukupolvi-Petty S, O'Brien KM, Johnson S, Fremont DH, Diamond MS.

J Virol. 2010 Oct;84(20):10630-43. doi: 10.1128/JVI.01190-10. Epub 2010 Aug 11.

9.

Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.

Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, Williams KL, Johnson S, Rico-Hesse R, Harris E, Pierson TC, Fremont DH, Diamond MS.

J Virol. 2010 Sep;84(18):9227-39. doi: 10.1128/JVI.01087-10. Epub 2010 Jun 30.

10.

The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1.

Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, Kim T, O'Brien KM, Nelson CA, Johnson S, Fremont DH, Diamond MS.

PLoS Pathog. 2010 Apr 1;6(4):e1000823. doi: 10.1371/journal.ppat.1000823.

11.

Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype.

Rodrigo WW, Block OK, Lane C, Sukupolvi-Petty S, Goncalvez AP, Johnson S, Diamond MS, Lai CJ, Rose RC, Jin X, Schlesinger JJ.

Virology. 2009 Nov 25;394(2):175-82. doi: 10.1016/j.virol.2009.09.024. Epub 2009 Oct 14.

12.

On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes.

Rajamanonmani R, Nkenfou C, Clancy P, Yau YH, Shochat SG, Sukupolvi-Petty S, Schul W, Diamond MS, Vasudevan SG, Lescar J.

J Gen Virol. 2009 Apr;90(Pt 4):799-809. doi: 10.1099/vir.0.006874-0. Epub 2009 Mar 4.

13.

Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins.

Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, Sukupolvi-Petty S, Sedlak D, Fremont DH, Chipman PR, Roehrig JT, Diamond MS, Kuhn RJ, Rossmann MG.

Nat Struct Mol Biol. 2008 Mar;15(3):312-7. doi: 10.1038/nsmb.1382. Epub 2008 Feb 10.

PMID:
18264114
14.

Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes.

Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, Roehrig JT, Gromowski GD, Barrett AD, Fremont DH, Diamond MS.

J Virol. 2007 Dec;81(23):12816-26. Epub 2007 Sep 19.

15.

Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein.

Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, Sukupolvi-Petty S, Marri A, Lachmi BE, Olshevsky U, Fremont DH, Pierson TC, Diamond MS.

J Virol. 2006 Dec;80(24):12149-59. Epub 2006 Oct 11.

Supplemental Content

Loading ...
Support Center